Compares a magnet-based bowel surgery with semaglutide for obesity and type 2 diabetes
Compares a magnetic bowel surgery with semaglutide in adults with obesity and diabetes.
Plain-language title generated from the registry record
Registry title: Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Key facts
- Where
- Westmount, CanadaSee the site
Where in Canada
- Westmount Surgical CenterWestmount, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GT Metabolic Solutions, Inc.
- Trial code
- NCT07317115
- Record updated
- 19 May 2026
- Original description
Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).Read full original descriptionShow less
Magnetic Compression Anastomosis in Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes (MAGvMED Study)
Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).
Inclusion: Body Mass Index (BMI) between 30 - 40 kg/m2 and qualifies for obesity treatment at the discretion of the treating investigator (i.e., must be assessed to qualify for both surgery and medication treatment to justify randomization); Type 2 diabetes (T2D defined as HbA1c ≥ 6.5%); Participant agrees to refrain from additional metabolic and bariatric (MBS) or reconstructive surgery that would affect body weight for the duration of the study; Participant agrees to refrain from taking any additional semaglutide-containing or other GLP-1RA medication for the duration of the study, regardless of randomization assignment (i.e., Surgery or Medication); Participant has been informed of the nature of the study and is willing and able to comply with requirements, including randomization, and provides written informed consent to participate in the study.
Exclusion: Meets any of the contraindications for either treatment arm (Surgery: Magnet System; or Medication: semaglutide), thereby prohibiting randomization; Current or previous metabolic and bariatric surgery (MBS) treatment in the previous 12 months (e.g., sleeve gastrectomy, intragastric balloons, adjustable gastric banding); Taking or treated with semaglutide, semaglutide-containing medications, or any other GLP-1RA medication in the previous 12 months; Currently participating in an investigational drug, biologic, or medical device or other interventional clinical study; Presence of other anatomic or comorbid conditions, or medical, social or psychological conditions that, in the investigator's opinion, would contraindicate either treatment arm or could limit the participant's ability to participate in the clinical study or to comply with follow-up requirements; Pregnant, lactating or planning pregnancy during the clinical study and follow-up period.